Part Used : ใบ
Activity : CYP2E1 INHIBITION
Solvent/Active Compound : -
Type of experiment : human
Type of animal : -
Type of study : Open trial
N(Total) : 12 (M/F=6/6)
N(Treatment) : 12 (M/F=6/6)
Sex : Both sex
Age : 67+/-5.2 yrs.
Route : Oral administration
Dose/Conc.(herb) : 60 mg four times daily (standardized to 24% flavones glycoside and 6% terpene lactones)
Duration : 28 days
Type of interaction : Pharmacokinetics
Interaction with drug : Chlorzoxazone
Dose/Conc.(drug) : 500 mg
Remark : Long-term administration of G. biloba had no modulatary effect on CYP2E1.
Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
